Concepedia

Publication | Open Access

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

DOIFull Paper Access

1.1K

Citations

16

References

2017

Year

Charles V. Pollack, Paul Reilly, Joanne van Ryn, John W. Eikelboom, Stephan Glund, Richard A. Bernstein, Robert Dubiel, Menno V. Huisman, Elaine M. Hylek, Pieter W. Kamphuisen,
New England Journal of Medicine

Abstract

In emergency situations, idarucizumab rapidly, durably, and safely reversed the anticoagulant effect of dabigatran. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947 .).

References

YearCitations

Page 1